4
Participants
Start Date
December 31, 2015
Primary Completion Date
March 29, 2018
Study Completion Date
March 29, 2018
ceritinib
Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
Laura & Isaac Permutter Cancer Center at NYU Langone, New York
The Ohio State University, James Cancer Hospital, Columbus
University of Colorado Cancer Center, Aurora
USC/Norris Comprehensive Cancer Center, Los Angeles
Swedish Cancer Institute, Seattle
Yale University, Yale Cancer Center, New Haven
Lead Sponsor
Collaborators (1)
University of Colorado, Denver
OTHER
Novartis
INDUSTRY
Criterium, Inc.
INDUSTRY